Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.02M | $6.88M | $2.36M | $4.65M | $7.42M | $3.57M | $9.54M | $12.74M |
| Cost of Revenue | $163.55M | $118.01M | $82.26M | $53.31M | $42.53M | $42.67M | $66.45M | $96.17M |
| Gross Profit | $-156.53M | $-111.13M | $-79.90M | $-48.66M | $-35.12M | $-39.10M | $-56.91M | $-83.43M |
| Gross Margin | -2229.77% | -1614.53% | -3389.94% | -1046.23% | -473.39% | -1094.29% | -596.68% | -654.70% |
| Operating Expenses | $38.55M | $43.41M | $35.33M | $22.58M | $28.24M | $15.93M | $99.53M | $38.10M |
| Operating Income | $-195.08M | $-154.54M | $-115.23M | $-71.24M | $-63.35M | $-55.03M | $-156.44M | $-121.53M |
| Operating Margin | -2778.89% | -2245.27% | -4889.01% | -1531.78% | -854.06% | -1540.19% | -1640.13% | -953.68% |
| Net Income | $-157.86M | $-141.43M | $-112.33M | $-70.51M | $-59.78M | $-50.88M | $-151.18M | $-93.03M |
| Net Margin | -2248.76% | -2054.76% | -4765.59% | -1516.04% | -805.88% | -1423.96% | -1585.07% | -730.06% |
| EPS (Basic) | $-2.45 | $-2.92 | $-2.40 | $-1.64 | $-2.02 | $-3.51 | $-14.48 | $-10.86 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |